10-Q · February 19, 2026
Lakeside reported Q2 revenue of $7,012,633 and GAAP loss per share of $(0.08). Revenue and gross profit improved materially year-over-year (revenue +$3,417,044; gross profit swing +$1,952,524) while operating loss…
Earnings analysis · 10-Q
LSH earnings analysis
Filed May 19, 2026 · Our reading of the company's report
The latest report
Lakeside Holding Limited reported significant growth in Q2 2026 with revenue reaching $7 million, a 75% increase from Q1, and a notable improvement in gross margin to 27.2%. However, despite the revenue growth, the…
Read full summary
Lakeside Holding Limited reported significant growth in Q2 2026 with revenue reaching $7 million, a 75% increase from Q1, and a notable improvement in gross margin to 27.2%. However, despite the revenue growth, the company continues to operate at a loss with diluted EPS recorded at -0.08. Management has highlighted ongoing challenges related to regulatory pressures in China and a considerable loan receivable impacting liquidity.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.08
- Gross margin
- 27.2%
- Segment
- Pharmaceutical Distribution
What stood out
-
Revenue Growth of 75% in Q2 2026
Lakeside's revenue surged to $7 million for Q2 2026, up from $4 million in Q1, driven by pharmaceutical distribution business expansion.
-
Improvement in Gross Margin
Gross margin increased to 27.2% in Q2 2026, up from 18.2% in Q1 2026, indicating better cost management.
-
Increase in Active Customers
The number of active customers rose from 4 to 12 during Q2 2026, contributing to increased sales volume.
-
Decrease in Interest Expense
Interest expenses decreased to $26,733 in Q2 2026 from $40,541 in Q1 2026, reflecting reduced financing costs.
-
Liquidity Position Improved
Current assets increased to approximately $17 million as of March 31, 2026, compared to $10 million in June 2025, enhancing liquidity.
-
Gain from Discontinued Operations
A gain of $2,556,315 from the sale of ABL Chicago was recorded in Q2 2026, contributing positively to the overall financials.
What to watch
-
High Dependence on Loan Receivable
Liquidity is significantly influenced by a $8.7 million loan receivable, representing 49% of total current assets.
-
Regulatory Risks in China
The pharmaceutical business operates under stringent regulations in China, which could affect pricing and sales.
-
Continued Operating Losses
Net loss from continuing operations was $3.5 million for the nine months ended March 31, 2026, indicating ongoing financial challenges.
Management's outlook
Management did not provide explicit guidance but pointed to continued focus on expanding the pharmaceutical distribution business.
Earlier filings 4
10-Q · November 19, 2025
Lakeside reported quarterly revenue of $6,099,889 (up from $4,081,554 a year earlier) with gross profit of $1,108,767 and a narrower loss per share of $(0.09) versus $(0.18) in the year-ago quarter. However, the company…
10-Q · May 15, 2025
Lakeside reported Q3 revenue of $3,803,140 and GAAP loss per share of $(0.14). Gross profit was $715,851 (≈18.8% of revenue) but operating loss widened to $(1,074,183) driven by a $1,680,339 increase in G&A for the…
10-Q · February 14, 2025
Lakeside reported Q2 revenue of $3,595,589 (down from $4,916,103 a year earlier) and a GAAP loss per share of $(0.26). Gross profit for the quarter was a loss of $42,231 (gross margin ≈ -1.2%), and operating loss was…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.